The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L).
Tamas Hickish
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim
Other Remuneration - Boehringer Ingelheim
Ling-Ming Tseng
No relevant relationships to disclose
Ajay O. Mehta
No relevant relationships to disclose
Janice Tsang
No relevant relationships to disclose
Nadezhda Kovalenko
No relevant relationships to disclose
Dmitry Udovitsa
No relevant relationships to disclose
Katy Pelling
Employment or Leadership Position - Boehringer Ingelheim
Martina Maria Uttenreuther-Fischer
Employment or Leadership Position - Boehringer Ingelheim
Chiun-Sheng Huang
No relevant relationships to disclose